文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

局限性前列腺癌经会阴超声图像引导放疗的治疗结果

Treatment outcome of localized prostate cancer using transperineal ultrasound image-guided radiotherapy.
PubMed 文献 · Radiat Oncol · 2024-08-01

本研究回顾性分析124例局限性前列腺癌患者接受经会阴超声图像引导放疗(TPUS-IGRT)的结果。5年生化前列腺特异性抗原无复发生存率低危为100%、中危为92.9%、高危/极高危为93.2%,2级及以上晚期泌尿生殖毒性和胃肠道毒性分别为7.4%和6.5%。作者认为TPUS-IGRT耐受性良好,其bPFS和晚期毒性发生率与其他图像引导放疗来源的报告几乎相当。

要点

  • 124例局限性前列腺癌患者接受TPUS-IGRT,123例完成放疗。
  • 5年bPFS:低危100%、中危92.9%、高危/极高危93.2%(Phoenix法)。
  • 2级及以上晚期毒性:泌尿生殖7.4%、胃肠道6.5%。

核心结论

  • 这些结果提示TPUS-IGRT耐受性良好,因为bPFS和晚期毒性发生率与其他图像引导放疗来源的报告几乎相当。

研究设计与样本

  • 回顾性分析124例局限性前列腺癌患者,中位年龄74岁(范围46-84岁),于2016年4月至2021年10月期间接受经会阴超声图像引导放疗(TPUS-IGRT,Clarity Autoscan系统;CAS,Elekta;瑞典斯德哥尔摩),用于根治性或激素诱导后治疗。
  • 按美国国家综合癌症网络2019年风险分组:低危7例、良好中危25例、不良中危42例、高危/极高危50例;95例接受新辅助激素治疗。

主要发现

  • 123例完成放疗全程,5年总生存率为95.9%。
  • 5年生化前列腺特异性抗原无复发生存率(bPFS,Phoenix法):低危100%、中危92.9%、高危/极高危93.2%。
  • 5年2级及以上晚期毒性发生率:泌尿生殖器官7.4%、胃肠道器官6.5%。
  • 比较≤76 Gy组与78 Gy组,泌尿生殖和胃肠道器官的晚期毒性发生率在78 Gy组均更高。
  • 85例患者共3135次分次治疗中实施了实时前列腺分次内监测(RTPIFM),其中1008次分次(32.1%)在开始照射后至少重新校正一次。

关键数值与推荐

  • 计划靶区外扩:大多数病例直肠方向3 mm,头脚方向5-7 mm,前/右/左方向5 mm。
  • 原则处方剂量:低危74 Gy,良好中危76 Gy,不良中危及以上76-78 Gy。
  • 当检测到位移2-3 mm或以上时,暂停照射,患者待命进行前列腺复位/重新校正。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We report the results of a retrospective analysis of localized prostate cancer (LPCa) treated with transperineal ultrasound image-guided radiotherapy (TPUS-IGRT). METHODS: A total of 124 patients (median age: 74 y, 46-84 y) with LPCa who underwent TPUS-IGRT (Clarity Autoscan system; CAS, Elekta; Stockholm, Sweden) between April 2016 and October 2021 for curative/after hormone induction were enrolled. The number of patients by risk (National Comprehensive Cancer Network 2019) was 7, 25, 42, and 50 for low (LR), good intermediate (good IR), poor intermediate (poor IR), and high (HR)/very high (VHR), respectively. Ninety-five patients were given neoadjuvant hormonal therapy. The planning target volume margin setting was 3 mm for rectal in most cases, 5-7 mm for superior/inferior, and 5 mm for anterior/right/left. The principle prescribed dose is 74 Gy (LR), 76 Gy (good IR), and 76-78 Gy (poor IR or above). CAS was equipped with a real-time prostate intrafraction monitoring (RTPIFM) system. When a displacement of 2-3 mm or more was detected, irradiation was paused, and the patients were placed on standby for prostate reinstatement/recorrection. Of the 3135 fractions in 85 patients for whom RTPIFM was performed, 1008 fractions (32.1%) were recorrected at least once after starting irradiation. RESULTS: A total of 123 patients completed the radiotherapy course. The 5-year overall survival rate was 95.9%. The 5-year biological prostate-specific antigen relapse-free survival rate (bPFS) was 100% for LR, 92.9% for intermediate IR, and 93.2% for HR/VHR (Phoenix method). The 5-year late toxicity rate of Grade 2+ was 7.4% for genitourinary (GU) and 6.5% for gastrointestinal (GI) organs. Comparing the ≤ 76 Gy group to the 78 Gy group for both GU and GI organs, the incidence was higher in the 78 Gy group for both groups. CONCLUSION: These results suggest that TPUS-IGRT is well tolerated, as the bPFS and incidence of late toxicity are almost comparable to those reported by other sources of image-guided radiotherapy.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Takai K, Watanabe R, Hyogo KI, et al. Treatment outcome of localized prostate cancer using transperineal ultrasound image-guided radiotherapy. Radiat Oncol. 2024. PMID: 39090614. doi:10.1186/s13014-024-02490-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。